Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

13.43 -0.22 (-1.61%)
Delayed Quote Updated: 10:49 AM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Syndax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Syndax (SNDX) Q2 2026 Earnings Call Transcript ↗
Revenue surged 92% year-over-year to $72.8 million, driven by Revuforj and Niktimvo. 
Via The Motley Fool
Topics Earnings
News headline image
Syndax Pharmaceuticals Q2 Earnings Call Highlights ↗
Syndax Pharmaceuticals (NASDAQ:SNDX) reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic... 
Via MarketBeat
Topics Earnings
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Drop as Q2 Revenue and EPS Miss Estimates ↗
Via Chartmill
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Stock Slides After Q1 Revenue Misses Street Forecasts Despite 224% Growth ↗
Via Chartmill
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template ↗
Via Chartmill
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q4 2025 Results with Revenue Beat and Wider-Than-Expected Loss ↗
Via Chartmill
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push ↗
Syndax Pharmaceuticals (NASDAQ:SNDX) used a company R&D event to outline expansion plans for its approved medicines Revuforj and Niktimvo while introducing two pipeline assets aimed at non-small cell... 
Via MarketBeat
News headline image
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Syndax Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
Syndax Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment. 
Via The Motley Fool
News headline image
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Syndax (SNDX) Q4 2025 Earnings Call Transcript ↗
Syndax (SNDX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Is Syndax Stock Down Today? ↗
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) are trading lower Friday following approval of one of its treatments from the U.S.'s Food and Drug Administration. 
Via Benzinga
News headline image
Where Syndax Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗
Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential. 
Via Benzinga
News headline image
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Deep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
Syndax (SNDX) Q2 Revenue Jumps 986% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower EPS Loss ↗
Syndax Pharmaceuticals reported mixed Q2 2025 results, beating revenue estimates with $37.96M but posting an EPS loss of ($0.83). Revuforj sales surged 43%, while shares dipped 3.66% post-earnings. 
Via Chartmill
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.